PUBLIC COMPANY
save$HROWHARROW, INC.
$HROW39.48-1.39%Nashville, TN, USupdated 13h ago
community read0 votes
pipeline
12
marketed
9
phase 3
2
catalysts ytd
6
approvals ytd
2
recalls ytd
0
Pipeline(12)
pipeline depth12 products
1Phase 22Phase 39Marketed
Marketed
(dexamethasone + tobramycin)
Ocular Inflammation
MarketedFlarex
Anterior Segment Inflammation
MarketedIheezo
Local Anesthetic Effect
MarketedMaxidex
Allergic Conjunctivitis
MarketedNevanac
Ocular Pain (Eye Pain)
MarketedVigamox
Bacterial Conjunctivitis
Marketedapraclonidine hydrochloride
Ocular Hypertension
Marketednatamycin
Blepharitis
Marketednepafenac
Ocular Inflammation
Phase 3(ketamine + midazolam)
Sedation
Phase 3midazolam ODT
Sedation
Phase 2TRIAMCINOLONE ACETONIDE
Ocular Pain (Eye Pain)
Glucocorticoid receptor
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase4Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
- phase4The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine
Insider activity
source: SEC Form 4🐶 Hiring Signal
next earnings Nov 9, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that